Smith+Nephew Completes Acquisition of CartiHeal

Smith+Nephew completed the acquisition of CartiHeal, developer of Agili-C, a novel sports medicine technology for cartilage regeneration in the knee.

Agili-C is an off-the-shelf one-step treatment for osteochondral lesions with a broader indication than existing treatments. It is indicated to treat a wide patient population, including those with lesions in knees with mild to moderate osteoarthritis as well as the approximately 700,000 patients who receive cartilage repair annually in the U.S.

Smith+Nephew paid $180 million on completion, with up to a further $150 million contingent on future financial performance, as previously disclosed.

“With its proven superiority to the current standard of care, Agili-C has the potential to transform cartilage repair outcomes,” said Scott Schaffner, President of Sports Medicine, Smith+Nephew.

Source: Smith+Nephew